Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical

Retrieved on: 2023-09-11 20:26:54

Tags for this article:

Clusters of differentiation

Infectious causes of cancer

Programmed cell death protein 1

PD-1 and PD-L1 inhibitors

PD-L1

RNA interference

Liver cancer

Arbutus Biopharma Corporation

Click the tags to see associated articles and topics

Arbutus Announces Pipeline Updates and Dosing of the First Subject in the Phase 1a/1b Clinical. View article details on HISWAI: https://www.bakersfield.com/ap/news/arbutus-announces-pipeline-updates-and-dosing-of-the-first-subject-in-the-phase-1a-1b/article_9dcd6aec-08c1-5ece-9a61-1086b641168a.html

Excerpt

11, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company ...

Article found on: www.bakersfield.com

View Original Article